- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Michael Wang Discusses the Importance of Biosimilars in Cancer Care
Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.
Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.
Transcript:
What is your position on biosimilar use inpatients with diffues large B-cell lymphoma? Are you comfortable using biosimilar anticancer therapeutics?
The concept of biosimilars is very powerful and is totally a useful concept. Our healthcare costs are so high, if we don't use biosimilars, our prices will never go down. We cannot afford it. Also biosimilars, in large part, have very good efficacies. I encourage the idea and also the practice of using biosimilars. I am comfortable using biosimilars all the time. When my institution approves of a biosimilar, I have no problem with using it at all. In fact, I'll use it more than the regular high-priced drug.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
